About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Hepatology
›
top-articles
Department of Hepatology
9
(top 5%)
papers
2.8K
(top 1%)
citations
7
(top 5%)
h
-index
8
(top 5%)
g
-index
10
all documents
3.0K
doc citations
682
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet, The
2017
2,771
2
Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study
Hepatology
2017
79
3
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
Journal of Clinical Oncology
2018
40
4
LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
Annals of Oncology
2016
29
5
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Clinical Cancer Research
2016
26
6
Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis
Histopathology
2017
11
7
Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial
Annals of Oncology
2016
7
8
Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
Annals of Oncology
2017
5
9
4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment
Journal of Vascular and Interventional Radiology
2018
0
10
Validation of a screening algorithm for hepatic fibrosis by Doppler ultrasound and elastography in a general population
Acta Radiologica
0
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.